Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

NEXT STORY
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
PREV STORY
Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Outlook on the Homeopathy Global Market to 2028 – by Source, Type, Application, Distribution Channel and Geography

author_avatar
NASDAQ Market News

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

author_avatar
NASDAQ Market News

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) ...

author_avatar
NASDAQ Market News